U.S., Sept. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07172022) titled 'A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS)' on Sept. 11.
Brief Summary: The main purpose of this study is to evaluate the efficacy of crovalimab compared with placebo as an add-on therapy to vitamin K antagonist (VKA) in participants with APS.
Study Start Date: Dec. 05, 2025
Study Type: INTERVENTIONAL
Condition:
Antiphospholipid Syndrome
Intervention:
DRUG: Crovalimab
Crovalimab will be administered at a dose of 680 mg (for participants with BW >= 40 kilograms [kg] to = 100 kg), as a SC injection, at Weeks 1, 2, and 3 and Q4W from Week 5 onwards.
DRUG: Placebo
Placebo matching crovalimab ...